Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:08:33.573Z.
Calculation as of: 2026-10-06T17:08:33.573Z.
Quote observation: 2026-10-06T17:05:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 24a0b8a5defa6360a8df5348432e42fec2fdf5a1d44ff9a0d63a76d612d48360
PE RATIO
N/A
Market Cap
$1.09B
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.11B
PE Ratio
278.37
TTM Avg
283.35
3Y Avg
108.94
5Y Avg
117.69
Market Cap
$1.13B
PE Ratio
15.13
TTM Avg
11.54
3Y Avg
13.50
5Y Avg
19.40
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Replimune Group, Inc. (REPL) | $1.09B | N/A | N/A | N/A | N/A |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | N/A | N/A | N/A | N/A |
| IRadimed Corporation (IRMD)vs › | $1.08B | 47.28 | 53.07 | 41.22 | 45.14 |
| STAAR Surgical Company (STAA)vs › | $1.11B | 278.37 | 283.35 | 108.94 | 117.69 |
| OPKO Health, Inc. (OPK)vs › | $1.12B | N/A | 38.94 | 40.17 | 40.17 |
| Harrow Health, Inc. (HROW)vs › | $1.13B | N/A | 47.35 | 23.64 | 23.64 |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 15.13 | 11.54 | 13.50 | 19.40 |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.12B | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.03B | N/A | 5.99 | 5.99 | 5.99 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$13.01
Forward EPS (Est.)
$-2.89
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
